AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies
News Jan 12, 2010
AnaptysBio, Inc., announced that it has signed an agreement with Roche for the development of novel antibody therapeutics.
“We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”
Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) platform. Roche will receive a worldwide license to develop and commercialize antibodies optimized by AnaptysBio. In addition to a signing fee paid by Roche, AnaptysBio will be eligible to receive milestone payments and royalties upon product sales.
“AnaptysBio’s proprietary SHM platform provides a powerful new approach for evolving existing antibodies to meet challenging therapeutic design goals such as those specified by Roche,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”
APC Protein Deletion Disrupts Cell Signalling and Could Cause AutismNews
Researchers show deletion of the protein APC in progenitor cells leads to massive disruption of brain development and a signaling cascade previously linked to genes associated with autism.READ MORE
SCIEX Receive Science and Technology Award at HUPO 2017News
Two researchers from SCIEX received the HUPO 2017 award at the 16th Human Proteome Organization World Congress in Dublin, Ireland.READ MORE
Machine Learning to Increase the Pace of Brain Imaging AnalysisNews
New approach could allow doctors or researchers to quickly identify the data they need, and then rapidly fill in the fine details, making the process faster and more accurate.READ MORE